Nocturia
Conditions
Keywords
Nocturia, Pharmacokinetics, Pharmacodynamics, Water-loading, Elderly, Males
Brief summary
The main purpose of the study is to evaluate the way VA106483 enters and leaves the blood and tissues over time and how the drug acts on and in the body at various dose levels compared to placebo in the same volunteer.
Detailed description
VA106483 is intended to be used as a treatment for patients suffering from nocturia (defined as waking to urinate at least once per night between periods of sleep). Nocturia is a condition that often worsens as sufferers get older. This may be due to an over-active bladder muscle, the bladder being able to hold less urine at night-time or over production of urine in the bladder at night. The only antidiuretic approved for the treatment (in some countries) of nocturia is the peptide drug, desmopressin. However, as it can cause hyponatraemia in a proportion of patients above the age of 65 years it is contra-indicated in the elderly. This side-effect has not been observed with VA106483, making it potentially suitable for treating the elderly. The purpose of this study is to confirm that duration of action of VA106483 can be effectively controlled by dose and therefore that satisfactory clinical outcome in the treatment of nocturia can be achieved by individual dose titration. Subjects will be water-loaded, dosed with either VA106483 or placebo and then urine production will be monitored to assess any anti-diuretic effect.
Interventions
DRUGVA106483
Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
DRUGPlacebo
Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Sponsors
Vantia Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male, Age: 65 years and above * Using adequate contraception * Medical history without clinically significant pathologies; no evidence of serious pathology or disease * Physical examination parameters without signs of serious disease * No clinically significant ECG and lab safety tests (sodium must be within normal range) * Willing and able to participate and provides written informed consent
Exclusion criteria
* Cardiac insufficiency; signs or symptoms suggestive of heart failure or requiring treatment with diuretics * Supine arterial blood pressure higher than 170/100 mmHg or less than 105/60 mm Hg * Presence of poorly controlled endocrine disorders * Renal insufficiency, active hepatic and/or biliary disease * Hyponatraemia. Serum sodium level must be within normal limits * Syndrome of inappropriate antidiuretic hormone (ADH) secretion * Symptoms suggestive of psychogenic or habitual polydipsia or of diabetes insipidus * Known hypersensitivity to the IP or any constituent of the IP * Use of any non-prescription preparation within 72 hours prior to study entry, with the exception of defined pain killers * A history of alcohol abuse or drug addiction within the last 2 years * Positive screen for HIV, hepatitis B or C * Currently taking any diuretics or any concomitant medication known to be a cytochrome 3A4 inhibitor * Other protocol defined eligibility criteria may apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine volume and osmolality and plasma PK assessments | 24 Hours |
Countries
United States
Outcome results
None listed